PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR 2020; 4(02): 098-106
DOI: 10.1055/s-0040-1715774
Guidelines

Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I

Pankaj Gupta 
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Naveen Kalra
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Shyamkumar N. Keshava
2   Department of Interventional Radiology, Division of Clinical Radiology, Christian Medical College, Vellore, Tamil Nadu, India
,
Sreedhara B. Chaluvashetty
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Amar Mukund
3   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
,
Shuvro H. Roy-Choudhury
4   Department of Radiology, NH Group of Hospitals, Kolkata, West Bengal, India
,
Sanjay Saran Baijal
5   Department of Interventional Radiology, Medanta, The Medicity, Gurgaon, Haryana, India
,
Anubhav Khandelwal
5   Department of Interventional Radiology, Medanta, The Medicity, Gurgaon, Haryana, India
,
Venkatesh Hosur Ananthashayana
3   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
,
Sathya Narayanan R.
2   Department of Interventional Radiology, Division of Clinical Radiology, Christian Medical College, Vellore, Tamil Nadu, India
,
Suyash Kulkarni
6   Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nitin Sudhakar Shetty
6   Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Arun Gupta
7   Department of Interventional Radiology, Sir Ganga Ram Hospital, New Delhi, Delhi, India
,
Sanjay Gupta
8   Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, United States
› Institutsangaben Financial Disclosures None.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Locoregional therapies play an important role in the management of hepatocellular carcinoma (HCC). Percutaneous ablation is one of the most commonly employed nonsurgical methods for treating very early and early HCC. For small HCCs, ablation is potentially curative and competes with surgical resection. The widespread availability and the spectrum of ablative techniques mandate uniform approach among interventional radiologists. Thus, it is desirable to have a consensus regarding various aspects of liver ablation. This article represents a consensus document of the experts from the Indian Society of Vascular and Interventional Radiology involved in the care of patients with HCC. The statements are presented in two parts.

Keywords

ablation - hepatocellular carcinoma - radiofrequency ablation


Publikationsverlauf

Artikel online veröffentlicht:
14. August 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017; 152 (04) 812-820.e5
    CrossrefPubMedGoogle Scholar
  • 2 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (04) 835-853
    CrossrefPubMedGoogle Scholar
  • 3 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
    CrossrefPubMedGoogle Scholar
  • 4 Shiina S, Sato K, Tateishi R. et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol 2018; 2018: 4756147
    CrossrefPubMedGoogle Scholar
  • 5 Atkins D, Best D, Briss PA. et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328 (7454) 1490
    CrossrefPubMedGoogle Scholar
  • 6 Izumi N, Hasegawa K, Nishioka Y. et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). J Clin Oncol 2019; 37 (15) 4002
    CrossrefPubMedGoogle Scholar
  • 7 Xu Q, Kobayashi S, Ye X, Meng X. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep 2014; 4: 7252
    CrossrefPubMedGoogle Scholar
  • 8 Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Pinna AD. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (26) 4106-4118
    CrossrefPubMedGoogle Scholar
  • 9 Xu XL, Liu XD, Liang M, Luo BM. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology 2018; 287 (02) 461-472
    CrossrefPubMedGoogle Scholar
  • 10 Tian G, Yang S, Yuan J. et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open 2018; 8 (10) e021269
    CrossrefPubMedGoogle Scholar
  • 11 Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, Ferko N, Amaral JF. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol 2019; 17 (01) 98
    CrossrefPubMedGoogle Scholar
  • 12 Cucchetti A, Piscaglia F, Cescon M. et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59 (02) 300-307
    CrossrefPubMedGoogle Scholar
  • 13 Lee MW, Kang D, Lim HK. et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020; 30 (04) 2391-2400
    CrossrefPubMedGoogle Scholar
  • 14 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
    CrossrefPubMedGoogle Scholar
  • 15 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 16 Ng KK, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104 (13) 1775-1784
    CrossrefPubMedGoogle Scholar
  • 17 Lin Y, Wen Q, Guo L, Wang H, Sui G, Sun Z. A network meta-analysis on the efficacy and prognosis of different interventional therapies for early-stage hepatocellular carcinoma. Int J Hyperthermia 2018; 35 (01) 450-462
    CrossrefPubMedGoogle Scholar
  • 18 Saviano A, Iezzi R, Giuliante F. et al. HepatoCATT Study Group. Liver resection versus radiofrequency ablation plus transcatheter arterial chemoembolization in cirrhotic patients with solitary large hepatocellular carcinoma. J Vasc Interv Radiol 2017; 28 (11) 1512-1519
    CrossrefPubMedGoogle Scholar
  • 19 Iezzi R, Pompili M, La Torre MF. et al. HepatoCATT Study Group for the Multidisciplinary Management of HCC. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis 2015; 47 (03) 242-248
    CrossrefPubMedGoogle Scholar
  • 20 Peng B. Hepatic Resection Versus Transarterial Chemoembolization Plus Radiofrequency Ablation for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma (NCT02616926). Available at: https://clinicaltrials.gov/ct2/show/NCT02616926. Accessed August 5, 2020
    PubMed
  • 21 Liao M, Zhong X, Zhang J. et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: a prospective randomized trial. J Surg Oncol 2017; 115 (08) 971-979
    CrossrefPubMedGoogle Scholar
  • 22 Fukuda K, Mori K, Hasegawa N. et al. Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide. Jpn J Radiol 2019; 37 (07) 555-563
    CrossrefPubMedGoogle Scholar
  • 23 Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 2010; 195 (03) 758-765
    CrossrefPubMedGoogle Scholar
  • 24 Kim YK, Kim CS, Chung GH. et al. Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. AJR Am J Roentgenol 2006; 186 (Suppl. 05) S261-S268
    CrossrefPubMedGoogle Scholar
  • 25 Nishikawa H, Kita R, Kimura T. et al. Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis. Anticancer Res 2014; 34 (06) 3039-3044
    PubMedGoogle Scholar
  • 26 Nouso K, Ito Y, Kuwaki K. et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98 (07) 1161-1165
    CrossrefPubMedGoogle Scholar
  • 27 Wakuta A, Nouso K, Kariyama K. et al. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011; 81 (01) 39-44
    CrossrefPubMedGoogle Scholar
  • 28 Koda M, Ueki M, Maeda Y. et al. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res 2004; 29 (01) 18-23
    CrossrefPubMedGoogle Scholar
  • 29 Kuroda H, Kasai K, Kakisaka K. et al. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol Res 2010; 40 (05) 550-554
    CrossrefPubMedGoogle Scholar
  • 30 Hsu CY, Liu PH, Lee YH. et al. Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis. Ann Surg Oncol 2015; 22 (04) 1324-1331
    CrossrefPubMedGoogle Scholar
  • 31 Hsu CY, Liu PH, Lee YH. et al. Hepatocellular carcinoma patients with performance status 1 deserve new classification and treatment algorithm in the BCLC system. Medicine (Baltimore) 2015; 94 (29) e1223
    CrossrefPubMedGoogle Scholar
  • 32 Patel IJ, Davidson JC, Nikolic B. et al. Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012; 23 (06) 727-736
    CrossrefPubMedGoogle Scholar
  • 33 Goto E, Tateishi R, Shiina S. et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J Clin Gastroenterol 2010; 44 (05) 374-380
    CrossrefPubMedGoogle Scholar
  • 34 Lee HS, Park SY, Kim SK. et al. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol 2012; 18 (03) 302-308
    CrossrefPubMedGoogle Scholar
  • 35 Pang Q, Qu K, Zhang JY. et al. The prognostic value of platelet count in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94 (37) e1431
    CrossrefPubMedGoogle Scholar
  • 36 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63 (02) 566-573
    CrossrefPubMedGoogle Scholar
  • 37 O’Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology 2019; 157 (01) 34-43.e1
    CrossrefPubMedGoogle Scholar
  • 38 Lee LH, Hwang JI, Cheng YC. et al. Comparable outcomes of ultrasound versus computed tomography in the guidance of radiofrequency ablation for hepatocellular carcinoma. PLoS One 2017; 12 (01) e0169655
    CrossrefPubMedGoogle Scholar
  • 39 Kitada T, Murakami T, Kuzushita N. et al. Effectiveness of real-time virtual sonography-guided radiofrequency ablation treatment for patients with hepatocellular carcinomas. Hepatol Res 2008; 38 (06) 565-571
    CrossrefPubMedGoogle Scholar
  • 40 Kim JE, Kim YS, Rhim H. et al. Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertiary center: analysis focused on the feasibility with the use of ultrasonography guidance. Eur J Radiol 2011; 79 (02) e80-e84
    CrossrefPubMedGoogle Scholar
  • 41 Clasen S, Boss A, Schmidt D. et al. MR-guided radiofrequency ablation in a 0.2-T open MR system: technical success and technique effectiveness in 100 liver tumors. J Magn Reson Imaging 2007; 26 (04) 1043-1052
    CrossrefPubMedGoogle Scholar
  • 42 Clasen S, Rempp H, Boss A. et al. MR-guided radiofrequency ablation of hepatocellular carcinoma: long-term effectiveness. J Vasc Interv Radiol 2011; 22 (06) 762-770
    CrossrefPubMedGoogle Scholar
  • 43 Clasen S, Rempp H, Hoffmann R, Graf H, Pereira PL, Claussen CD. Image-guided radiofrequency ablation of hepatocellular carcinoma (HCC): is MR guidance more effective than CT guidance?. Eur J Radiol 2014; 83 (01) 111-116
    CrossrefPubMedGoogle Scholar
  • 44 Yuan C, Yuan Z, Cui X. et al. Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma. J Cancer Res Ther 2019; 15 (04) 784-792
    CrossrefPubMedGoogle Scholar
  • 45 Lee MW, Rhim H, Cha DI. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol 2012; 198 (06) 1438-1444
    CrossrefPubMedGoogle Scholar
  • 46 Song KD, Lee MW, Rhim H. et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology 2018; 288 (03) 878-886
    CrossrefPubMedGoogle Scholar
  • 47 Krücker J, Xu S, Glossop N. et al. Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J Vasc Interv Radiol 2007; 18 (09) 1141-1150
    CrossrefPubMedGoogle Scholar
  • 48 Tomonari A, Tsuji K, Yamazaki H. et al. Feasibility of the virtual needle tracking system for percutaneous radiofrequency ablation of hepatocellular carcinoma. Hepatol Res 2013; 43 (12) 1352-1355
    CrossrefPubMedGoogle Scholar
  • 49 Engstrand J, Toporek G, Harbut P, Jonas E, Nilsson H, Freedman J. Stereotactic CT-guided percutaneous microwave ablation of liver tumors with the use of high-frequency jet ventilation: an accuracy and procedural safety study. AJR Am J Roentgenol 2017; 208 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 50 Odisio BC, Richter M, Aloia TA. et al. Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 2016; 20 (08) 1428-1434
    CrossrefPubMedGoogle Scholar
  • 51 Bhatia SS, Spector S, Echenique A. et al. Is antibiotic prophylaxis for percutaneous radiofrequency ablation (RFA) of primary liver tumors necessary? Results from a single-center experience. Cardiovasc Intervent Radiol 2015; 38 (04) 922-928
    CrossrefPubMedGoogle Scholar
  • 52 Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226 (02) 441-451
    CrossrefPubMedGoogle Scholar
  • 53 Hsieh YC, Limquiaco JL, Lin CC, Chen WT, Lin SM. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol (NY) 2019; 44 (03) 1141-1151
    CrossrefPubMedGoogle Scholar
  • 54 Zhang M, Liang P, Cheng ZG, Yu XL, Han ZY, Yu J. Efficacy and safety of artificial ascites in assisting percutaneous microwave ablation of hepatic tumours adjacent to the gastrointestinal tract. Int J Hyperthermia 2014; 30 (02) 134-141
    CrossrefPubMedGoogle Scholar
  • 55 Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009; 19 (11) 2630-2640
    CrossrefPubMedGoogle Scholar
  • 56 Hermida M, Cassinotto C, Piron L. et al. Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. Int J Hyperthermia 2018; 35 (01) 90-96
    CrossrefPubMedGoogle Scholar
  • 57 Nishimura M, Nouso K, Kariyama K. et al. Safety and efficacy of radiofrequency ablation with artificial ascites for hepatocellular carcinoma. Acta Med Okayama 2012; 66 (03) 279-284
    PubMedGoogle Scholar
  • 58 Cha J, Rhim H, Lee JY. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: assessment of safety in patients with ascites. AJR Am J Roentgenol 2009; 193 (05) W424-9
    CrossrefPubMedGoogle Scholar
  • 59 Sherwani AK, Weis BA, Guynan J. et al. Evaluation of post-procedure hemorrhage in patients with ascites undergoing treatment of hepatic malignancy with thermal ablation utilizing microwave technology. J Clin Oncol 2018; 34 (15) e15582
    PubMedGoogle Scholar